Cell & gene therapy neurodegeneration pivot + delivery + FDA reg
Key Questions
What is the current scale of CRISPR-based therapies like CASGEVY?
CASGEVY has treated over 500 patients, reflecting growing adoption of approved cell and gene therapies. ASGCT reports 42 approved therapies overall.
Which gene therapies received recent regulatory acceleration?
Regeneron's Otarmeni received EMA accelerated assessment for genetic hearing loss. Taysha's TSHA-102 earned FDA Breakthrough Therapy Designation for Rett syndrome.
How are LNPs being engineered for better RNA delivery?
Advances focus on optimizing RNA payload distribution within LNPs to improve CRISPR editing efficiency. This work extends to broader RNA therapeutic applications.
What screening platforms support C9orf72-related therapies?
Arrayed dual-gRNA CRISPR screening platforms are advancing targeted therapies for C9-FTD/ALS. They establish frameworks for more precise gene editing approaches.
What regulatory changes aim to speed rare disease therapies?
The UK's MHRA proposed a new framework to accelerate approvals for rare disease treatments. This responds to ongoing FDA and EMA evaluation challenges.
How are companies addressing AAV safety in gene therapy?
Ongoing research targets AAV safety profiles alongside CMC and integration barriers. Intellia and others explore LNP-based CRISPR alternatives.
What pipelines are advancing from Lexeo and Lilly?
Lexeo and Lilly are progressing gene therapy candidates for neurodegenerative conditions. These build on uniQure and Ultragenyx platform advances.
What barriers remain in cell and gene therapy commercialization?
Key hurdles include manufacturing, regulatory integration, and investor concerns amid FDA uncertainty. Efforts focus on removing development barriers for broader access.
CRISPR CASGEVY >500 pts; ASGCT 42 approved; uniQure/Ultragenyx/Regeneron advances incl. Otarmeni EMA accelerated assessment; Lexeo/Lilly pipelines; AAV safety. New: Taysha TSHA-102 Rett BTD; dual-gRNA C9orf72 screening; LNP RNA payload engineering; Intellia LNP CRISPR; RNA patching; CRISPR nickase HD; CGT CMC/integration barriers.